Serum Evaluation of Helicobacter pylori in Patients with Multiple Sclerosis

被引:0
作者
Meshkat, Mojtaba [1 ]
Behjati, Yeganeh [2 ]
Bakhshi, Mansooreh [3 ]
Meshkat, Zahra [4 ]
Mehr, Mina Yazdan [3 ]
Boostani, Reza [5 ]
Saeidi, Morteza [5 ]
Khoshakhlagh, Mahdieh [6 ]
Chechaklou, Amin Hooshyar [4 ]
Najjari, Mahya [3 ]
Abolbashari, Samaneh [4 ]
Gholoobi, Aida [7 ,8 ]
机构
[1] Islamic Azad Univ, Fac Med, Dept Community Med, Mashhad Med Sci, Mashhad, Razavi Khorasan, Iran
[2] Mashhad Univ Med Sci, Student Res Comm, Mashhad, Razavi Khorasan, Iran
[3] Mashhad Univ Med Sci, Dept Microbiol & Virol, Fac Med, Mashhad, Razavi Khorasan, Iran
[4] Mashhad Univ Med Sci, Antimicrobial Resistance Res Ctr, Mashhad, Razavi Khorasan, Iran
[5] Mashhad Univ Med Sci, Ghaem Hosp, Dept Neurol, Mashhad, Razavi Khorasan, Iran
[6] Mashhad Univ Med Sci, Dept Biochem, Fac Med, Mashhad, Razavi Khorasan, Iran
[7] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran
[8] Mashhad Univ Med Sci, Med Genet Res Ctr, Mashhad, Razavi Khorasan, Iran
关键词
Helicobacter pylori; Multiple Sclerosis; Serology; IgG Antibodies; INFECTION; RISK;
D O I
10.5812/ans-133607
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Multiple sclerosis (MS) is an autoimmune inflammatory disorder of the central nervous system of unknown etiology, which is believed to be caused by immune dysregulation triggered by genetic and environmental factors, leading to demyelination and axonal loss. Researchers consider infectious agents, like Helicobacter pylori, as these environmental factors. H. pylori can permanently infect someone's stomach and cause an acute or chronic inflammatory response, in which inflammatory mediators affect the brain and cause a pathologic disease. Methods: In this cross-sectional study, 38 patients with multiple sclerosis who were referred to the Neurology Clinic of Ghaem Hospital were included, and their serum samples were analyzed for IgM, IgA, and IgG antibodies against H. pylori by using enzyme-linkedimmunosorbentassay (ELISA). Resultswerecomparedwith the samples of 41 sex- andage-matched controls admitted to other wards of Ghaem Hospital & had no symptoms of MS. In the end, we analyzed the data with SPSS v.20. Results: In this study, 79 patients, including 38 patients with MS disease in the case group and 41 healthy individuals in the control group, were studied. These two groups had no significant differences in demographic characteristics, including age, gender, and occupation. H. pylori seropositivity was significantly higher in patients with MS than in controls (68.4% vs 39%) (P = 0.009). In addition, comparing H. pylori seropositivity in 20 of 30 patients with relapsing-remitting MS versus 6 of 8 patients with progressive MSsuggested a significant difference between these two groups (P = 0.030). Also, H. pylori seropositivityhadnosignificant difference between males and females (39.1% vs 58.9%). Conclusions: The prevalence of H. pylori seropositivity was significantly higher in patients with MS than in control, besides this seems more frequent in a progressive type of MS than in a relapsing-remitting one, suggesting that H. pylori might be a causal factor for developing & progressing MS and this may have an adverse impact on the prognosis and course of the disease.
引用
收藏
页数:7
相关论文
共 32 条
  • [11] Gavalas E, 2015, ANN GASTROENTEROL, V28, P353
  • [12] Relevance of Helicobacter pylori infection in Egyptian multiple sclerosis patients
    Gerges S.E.
    Alosh T.K.
    Khalil S.H.
    El Din M.M.W.
    [J]. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 54 (1)
  • [13] Ghasemi N, 2017, CELL J, V19, P1
  • [14] Goodin DS, 2014, HAND CLINIC, V122, P231, DOI 10.1016/B978-0-444-52001-2.00010-8
  • [15] Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey
    Gross, Hillary J.
    Watson, Crystal
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 1349 - 1357
  • [16] Epstein-Barr Virus and Systemic Autoimmune Diseases
    Houen, Gunnar
    Trier, Nicole Hartwig
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [17] Helicobacter pylori infection as a potential risk factor for multiple sclerosis
    Kountouras, Jannis
    Papaefthymiou, Apostolis
    Gavalas, Emmanuel
    Polyzos, Stergios A.
    Boziki, Marina
    Kyriakou, Panagiota
    Katsinelos, Panagiotis
    Zavos, Christos
    Liatsos, Christos
    Tzivras, Dimitri
    Tzitiridou-Chatzopoulou, Maria
    Dardiotis, Efthymios
    Deretzi, Georgia
    Vardaka, Elisabeth
    Doulberis, Michael
    [J]. MEDICAL HYPOTHESES, 2020, 143
  • [18] Lassmann H, 2004, TRENDS IMMUNOL, V25, P132, DOI 10.1016/j.it.2004.01.007
  • [19] B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients
    Lovett-Racke, Amy E.
    Gormley, Matthew
    Liu, Yue
    Yang, Yuhong
    Graham, Calsey
    Wray, Sibyl
    Racke, Michael K.
    Shubin, Richard
    Twyman, Cary
    Alvarez, Enrique
    Bass, Ann
    Eubanks, James L.
    Fox, Edward
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2019, 332 : 187 - 197
  • [20] Defining the clinical course of multiple sclerosis The 2013 revisions
    Lublin, Fred D.
    Reingold, Stephen C.
    Cohen, Jeffrey A.
    Cutter, Gary R.
    Sorensen, Per Soelberg
    Thompson, Alan J.
    Wolinsky, Jerry S.
    Balcer, Laura J.
    Banwell, Brenda
    Barkhof, Frederik
    Bebo, Bruce, Jr.
    Calabresi, Peter A.
    Clanet, Michel
    Comi, Giancarlo
    Fox, Robert J.
    Freedman, Mark S.
    Goodman, Andrew D.
    Inglese, Matilde
    Kappos, Ludwig
    Kieseier, Bernd C.
    Lincoln, John A.
    Lubetzki, Catherine
    Miller, Aaron E.
    Montalban, Xavier
    O'Connor, Paul W.
    Petkau, John
    Pozzilli, Carlo
    Rudick, Richard A.
    Sormani, Maria Pia
    Stueve, Olaf
    Waubant, Emmanuelle
    Polman, Chris H.
    [J]. NEUROLOGY, 2014, 83 (03) : 278 - 286